Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fourth Dose mRNA-1273 Vaccine in Sheba HCW Cohort
NCT05230953Phase 3Active, not recruiting
- Sponsor
- Sheba Medical Center
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of elasomeran in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Sheba Medical Center. Primary endpoints: Geometric mean of antibody titers at 6 months and Solicited and unsolicited adverse events at 6 months. Started Jan 2022; status: active, not recruiting.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05230953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05230953.